Epiconcept company

#ESCAIDE DAY 3: Congrats to Héloïse Lucaccioni presenting at the Fireside Session 11 - Childhood vaccinations: "Influenza vaccine effectiveness among children and adolescents: results from the European VEBIS primary care multicentre study in the 2022/23" Last day in Stockholm: discover the Group photo of our epidemiology team! Congrats to all of you for your presentations! 👏👏👏 Angie Rose Camelia Savulescu Valérie Nancey Lore Merdrignac Madelyne Rebischung-Cardon Miguel Angel Sanchez Ruiz Baltazar Nunes Anthony Nardone Diogo Marques James Humphreys Jennifer Howard Liliana Antunes #epidemiology #escaide #vaccineEffectiveness #sarsCov2 European Centre for Disease Prevention and Control (ECDC)

#ESCAIDE DAY 2: Congrats to Angie Rose presenting at the Fireside Session 7 Vaccine-preventable diseases 💉🦠: "Seasonal 2023/24 influenza A vaccine effectiveness: VEBIS European hospital multicentre study" (Presenting Jennifer Howard's Oral Presentation) #epidemiology #escaide #vaccineEffectiveness #sarsCov2 European Centre for Disease Prevention and Control (ECDC)

#ESCAIDE DAY 1: A busy day for our Epidemiology team 💉🦠: one presentation followed another, well done to all!👏👏👏 ✔️ Fireside Session 2 - COVID-19 - Camelia Savulescu: "Effectiveness of COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in the European Union multi-centre hospital healthcare worker cohort (VEBIS HCW), season 2023 – 2024" ✔️ Poster Tour 7 - Surveillance Systems - Diogo Marques: "Evaluation of the European severe acute respiratory infection surveillance, October 2023: useful, acceptable, and meets its main objective" ✔️ Poster Tour 7 - Surveillance Systems - Miguel Angel Sanchez Ruiz: "Surveillance of severe acute respiratory infections associated with SARS-CoV-2, influenza virus and RSV using ICD-10 codes: a case definition accuracy study across five European countries, 2021-2023" ✔️ Poster Tour 8 - COVID-19 - Baltazar Nunes: "XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during Omicron BA.2.86/JN.1 period among older adults in seven EU/EAA countries: ECDC VEBIS electronic health record network" ✔️ Poster Tour 8 - COVID-19 - James Humphreys: "Evaluation of an electronic health record-based multi-country network designed to monitor COVID-19 vaccine effectiveness in EU-EEA countries (October 2021 – February 2024)" ✔️ Poster Tour 8 - COVID-19 - Lore Merdrignac: "Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in adults aged >=65 years during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study 2023–2024" ✔️ Poster Tour 8 - COVID-19 - Madelyn Yiseth Rojas Castro (Presenting Liliana Antunes's Poster): "Effectiveness of the XBB.1.5 COVID-19 vaccines against hospitalisation during the BA.2.86 variant-predominant period in adults aged >=65 years: VEBIS European hospital multicentre study, 2023/24" #epidemiology #vaccineEffectiveness #sarsCov2 European Centre for Disease Prevention and Control (ECDC)

[EPIDEMIOLOGY] 📅 D-2 ESCAIDE 20-22 November 2024! 👩🏫 Our epidemiology team is getting set in 2 days for the new 2024 edition of Escaide in Stockholm & online! They will present (or support) the results of scientific publications produced recently! Most of them about Vaccine Effectiveness 🦠💉, such as: ✔️ 20/11/2024 11:00-12:30 Fireside Session 2 - COVID-19 Camelia Savulescu "Effectiveness of COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in the European Union multi-centre hospital healthcare worker cohort (VEBIS HCW), season 2023 – 2024" ✔️ 20/11/2024 15:30-16:30 Poster Tour 7 - Surveillance Systems Diogo Marques "Evaluation of the European severe acute respiratory infection surveillance, October 2023: useful, acceptable, and meets its main objective" ✔️ 20/11/2024 15:30-16:30 Poster Tour 7 - Surveillance Systems Miguel Angel Sanchez Ruiz "Surveillance of severe acute respiratory infections associated with SARS-CoV-2, influenza virus and RSV using ICD-10 codes: a case definition accuracy study across five European countries, 2021-2023" ✔️ 20/11/2024 15:30-16:30 Poster Tour 8 - COVID-19 Baltazar Nunes "XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during Omicron BA.2.86/JN.1 period among older adults in seven EU/EAA countries: ECDC VEBIS electronic health record network" ✔️ 20/11/2024 15:30-16:30 Poster Tour 8 - COVID-19 James Humphreys "Evaluation of an electronic health record-based multi-country network designed to monitor COVID-19 vaccine effectiveness in EU-EEA countries (October 2021 – February 2024)" ✔️ 20/11/2024 15:30-16:30 Poster Tour 8 - COVID-19 Lore Merdrignac "Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2 infection in adults aged >=65 years during the JN.1 lineage-predominant period, European VEBIS primary care multicentre study 2023–2024" ✔️ 20/11/2024 15:30-16:30 Poster Tour 8 - COVID-19 Madelyn Yiseth Rojas Castro (Presenting Liliana Antunes's Poster) "Effectiveness of the XBB.1.5 COVID-19 vaccines against hospitalisation during the BA.2.86 variant-predominant period in adults aged >=65 years: VEBIS European hospital multicentre study, 2023/24" ✔️ 21/11/2024 14:00-15:30 Fireside Session 7 Vaccine-preventable diseases Angie Rose (Presenting Jennifer Howard's Oral Presentation) "Seasonal 2023/24 influenza A vaccine effectiveness: VEBIS European hospital multicentre study" ✔️ 22/11/2024 14:00-15:30 Fireside Session 11 - Childhood vaccinations Héloïse Lucaccioni "Influenza vaccine effectiveness among children and adolescents: results from the European VEBIS primary care multicentre study in the 2022/23" #epidemiology #escaide #vaccineEffectiveness #sarsCov2 European Centre for Disease Prevention and Control (ECDC)

Antimicrobial resistance (AMR) is one of the greatest public health threats of our time, surpassing the impact of HIV or malaria*. 💊 ❗ The alarming data from 2019 alone reveals 4.95 million deaths associated with drug-resistant bacterial infections, and an additional 1.27 million deaths directly caused by AMR. IQLS is bringing everyone’s attention to recognize the importance of AMR during World Antimicrobial Awareness Week #WAAW! 💪 🌏 In response to this global health challenge, at IQLS we are committed to making a substantial impact through various public health initiatives: 🔹 Collaborating with Epiconcept company : Epidemiology - e-Health - Data science, we are actively engaged in a consortium to provide country support for advancing One Health responses against AMR in the Western Balkans for the European Centre for Disease Prevention and Control (ECDC). This project seeks to promote a One Health approach for AMR control, secure political commitment for national interventions, and facilitate the exchange of best practices among participating countries. Three country visits have been conducted, and an AMR roadmap has been developed for each. 🔹 IQLS is involved in the WHO Global Initiative to strengthen AMR diagnostic capacity, laboratory systems, and service delivery in low- and middle-income countries (LMICs). We have guided the development of a strategic and operational framework to establish well-functioning clinical bacteriology and mycology laboratories, essential in combatting AMR 🔹 We have been entrusted by the Diagnostic Microbiology Development Program (DMDP) to continue strengthening microbiology laboratories in Cambodia. Building on our longstanding collaboration, which resulted in the creation of the ISO 9001-certified media production facility (CMML), we will further enhance laboratory capacities through activities such as mentoring, training, and workshops, to provide high quality media and reinforce the detection and response as key to the fight against AMR. 🔹 In collaboration with the U.S. CDC's International Infection Control Program (IICP) that helps LMICs in implementing AMR surveillance systems, which are crucial for quality laboratory detection, IQLS is working on enhancing The Laboratory Assessment of Antibiotic Resistance Testing Capacity (LAARC) tool, developed by the CDC in 2017-2018, to address gaps in AMR detection. At IQLS we will continue our participation in this public health fight, confident that our collaborative efforts will soon lead to a sustainable and measurable impact. 🌍 #AMR #WAAW #WAAW2024 #PublicHealth #OneHealth

📣 [GROUPE] Dans le cadre de l’accélération du développement d’Epiconcept, les 4 associés [Loic Flachet, Guillaume Jeannerod, Valérie Nancey et Etienne Sevinévin] ont décidé d’ouvrir le capital d’Epiconcept à un nouvel actionnaire. Le choix s’est porté vers un acteur complémentaire dans le domaine de la santé et partageant la même vision du métier : le Groupe Softway Medical. En combinant leurs expertises en e-santé, épidémiologie et data science, les deux entreprises créent une complémentarité stratégique et renforcent leur capacité à répondre aux enjeux prioritaires des acteurs de santé publique, notamment en matière de prévention et d’amélioration de la santé des citoyens. « En rejoignant le Groupe Softway Medical, nous allons pouvoir étendre notre champ d’action, proposer nos expertises dans des secteurs complémentaires et accélérer les mises sur le marché. Nous partageons une vision commune de la santé connectée et de l’importance de la donnée pour une prise de décision éclairée. » souligne Guillaume JEANNEROD - Directeur Général d’Epiconcept Ensemble, nous consolidons notre expertise en matière de gestion de données, hébergement et protection des données sensibles. En savoir plus : 👉 https://lnkd.in/eFTDwWpf #esanté #ehealth #santépublique #ONG #hébergeur #donnéessanté

[EPIDEMIOLOGY] 📑 Discover the new article published on the Eurosurveillance website: "Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24", co-authored by our epidemiologists Camelia Savulescu & Anthony Nardone & VEBIS HCW VE study group funded by European Centre for Disease Prevention and Control (ECDC). Abstract: "COVID-19 vaccination recommendations include healthcare workers (HCWs). We measured COVID-19 vaccine effectiveness (CVE) of the autumn 2023 dose against laboratory-confirmed SARS-CoV-2 infection in a prospective cohort study of 1,305 HCWs from 13 European hospitals. Overall CVE was 22% (95% CI: −17 to 48), 49% (95% CI: −8 to 76) before and −11% (95% CI: −84 to 34) after the start of BA.2.86/JN.1 predominant circulation. Autumn 2023 COVID-19 vaccination led to a moderate-to-low reduction in SARS-CoV-2 infection incidence in HCWs. Monitoring of CVE is crucial for COVID-19 prevention." Read the complete article: 👇 https://lnkd.in/e2aVqviE Find all our scientific publications: 👉 https://lnkd.in/efsAUUMu #VaccineEffectiveness #SARSCov2 #epidemiology

📣 [RECRUTEMENT/ WE'RE HIRING] Notre équipe s'agrandit : Epiconcept propose 4 ouvertures de postes ! Our team is growing: Epiconcept is offering 4 new jobs! ✔️ Responsable de l'équipe Framework / Framework team Manager 📍 Paris - possibilité de télétravail total ou hybride / full or hybrid teleworking options ✔️ Senior epidemiologist 📍 Epiconcept headquarters are in Paris but offices are located in Spain, Portugal and the UK ✔️ Consultant web confirmé - Confirmed consultant ✔️ PHP developper 📍 Quatre Bornes - Maurice / Mauritius. Travail à domicile 3 jours par semaine / Work from home 3 days a week 👉 https://lnkd.in/e87xypva #emploi #IT #job #Mauritius #developer #webconsultant #hiring #epidemiology #framework

#FRIDAYREAD 📑 Discover the new article published on the The Lancet Group Regional Europe Health website: "COVID-19 vaccine effectiveness against SARS-CoV-2-confirmed hospitalisation in the eastern part of the WHO European Region (2022–2023): a test-negative case-control study from the EuroSAVE network", co-authored by our epidemiologists sandra Cohuet, James Humphreys, Jennifer Howard & Angie Rose. Background & Interpretation: "Understanding COVID-19 vaccine effectiveness (VE) in preventing severe disease is critical to inform vaccine policy. We used the test-negative design to estimate VE against SARS-CoV-2-confirmed hospitalisation in adults ≥18 years in the eastern WHO European Region. (...) During nearly two years of Omicron circulation in the eastern WHO European Region, COVID-19 vaccination reduced the risk of hospitalisations by more than half for 6 months following vaccination." Read the complete article: 👇 https://lnkd.in/e5n5CwgA Find all our scientific publications: 👉 https://lnkd.in/efsAUUMu #VaccineEffectiveness #SARSCov2 #epidemiology

[EVENEMENT] Notre équipe Dépistage e-SIS est actuellement au congrès à Nantes de la SFSPM (Société Française de Sénologie et de Pathologie Mammaire) qui se déroule du 6 au 8 novembre ! Cette 45ème édition de 2024 porte sur le thème "Prévention et Cancer du sein : Mythe ou Réalité au XXIème siècle". Les experts sont réunis pour faire progresser le diagnostic, la prévention et les thérapeutiques, promouvoir la recherche, améliorer et harmoniser la prise en charge des patientes et apporter une réelle expertise ! Depuis 2001, Epiconcept accompagne les CRCDC avec son système d’information e-SIS 3D et e-SIS Démat. Nos solutions sont destinées à optimiser le parcours du dossier patient pour les cancers du sein, du colorectal et du col de l’utérus). Notre solution informatique e-SIS, avec son module de dématérialisation des mammographies, permet d'optimiser les temps de traitement et facilite les secondes lectures 🔍 pour les professionnels de santé. #Dépistage #cancerdusein #prevention